End-Tidal CO2 (EtCO2) Monitoring in the Home

Published in Respiratory & Sleep on February 24, 2022

By Ron Hosp, MS, RRT

The End-tidal CO₂ (EtCO₂) test provides a non-invasive measurement of the patient’s ventilation, circulation, and metabolism. The observed results are EtCO₂, Respiratory Rate, Heart Rate, and Saturation (SpO₂).

Noninvasive capnography monitoring is indicated for patients that are experiencing or at risk of developing respiratory failure to assess if the patient is being adequately treated.

• Using high-flow oxygen (e.g., greater than 4 liters/minute)
• Positive Pressure Therapy
  • CPAP, BiPAP, respiratory assist device, or noninvasive ventilator

Patient conditions may include:

• Respiratory muscle fatigue
• COPD exacerbation
• Hypoventilation caused by CHF
• Circulatory compromise
• Indicator of bronchospasm in patients with asthma
• Drug intoxication

When a DME company adds capnography to their diagnostic service portfolio, it positions them apart from their competitors. The use of Masimo’s RAD 97 with capnography provides unique IDTF reporting capabilities through Breathe. 

Physicians and alternant care practitioners identify companies offering this level of service as being best qualified to care for patients diagnosed with chronic respiratory failure. 

VGM members have access to discounted pricing from our preferred contract partners and service providers. They create a pathway of patient care – from testing to reimbursement – helping you grow your business and show your value through reduced readmissions.  Breathe, Masimo, Philips Respironics, and Trace Medical provide these products. For more information on EtCO2, check VGM Respiratory’s guide, NIV for COPD: Using End-Tidal CO2 to Identify Patients Who Benefit.

TAGS

1. respiratory